Novel schizophrenia risk factor pathways regulate FEZ1 to advance oligodendroglia development

Article metrics

Abstract

Neuropsychiatric disorders, represented by schizophrenia, affect not only neurons but also myelinating oligodendroglia (OL), both contribute to the complex etiology. Although numerous susceptibility genes for schizophrenia have been identified, their function has been primarily studied in neurons. Whether malfunction of risk genes underlies OL defects in schizophrenia pathogenesis remains poorly understood. In this study, we investigated the function and regulation of the well-recognized schizophrenia risk factor, Fasciculation and Elongation Protein Zeta-1 (FEZ1), in OL. We found that FEZ1 is expressed in oligodendroglia progenitor cells (OPCs) derived from rodent brains and human induced pluripotent stem cells (iPSCs) in culture and in myelinating oligodendrocytes in the brain. In addition, a vigorous upregulation of FEZ1 occurs during OPC differentiation and myelinogenesis, whereas knockdown of FEZ1 significantly attenuates the development of OL process arbors. We further showed that transcription of the Fez1 gene in OL cells is governed by a sophisticated functional interplay between histone acetylation-mediated chromatin modification and transcription factors that are dysregulated in schizophrenia. At the post-transcriptional level, the selective RNA-binding protein QKI, a glia-specific risk factor of schizophrenia, binds FEZ1 mRNA. Moreover, QKI deficiency results in a marked reduction of FEZ1 specifically in OL cells of the quakingviable (qkv) hypomyelination mutant mice. These observations have uncovered novel pathways that involve multifaceted genetic lesions and/or epigenetic dysregulations in schizophrenia, which converge on FEZ1 regulation and cause OL impairment in neuropsychiatric disorders.

Introduction

Besides neuronal network defects, accumulating evidence from brain imaging and postmortem studies clearly demonstrates structural and functional impairment of myelinating oligodendroglia (OL) in major neuropsychiatric diseases1. Reduced OL density, aberrant expression of myelin-related genes, and white matter disruptions have been reported in the brains of schizophrenia, bipolar disease, and major depression patients2,3,4. Consequently, the contribution of OL and myelin defects on the complex etiology of psychiatric illnesses has been increasingly recognized in recent years. In fact, the first-episode schizophrenia patients already display compromised white matter integrity in cortical and subcortical brain regions5,6,7, suggesting that OL impairment is involved in early schizophrenia pathogenesis.

The identification of numerous schizophrenia-associated risk genes and familial transmission indicates the genetic component in schizophrenia pathogenesis8,9. However, the function of schizophrenia risk genes has been primarily investigated in neurons10,11. Whether malfunction of the same risk genes underlies OL impairment in schizophrenia pathogenesis remains elusive. In addition to the genetic variances, epigenetic abnormalities, including aberrant DNA and chromatin modifications, further increase the etiological complexity of psychiatric diseases12. Nonetheless, despite the key roles of epigenetic mechanisms in advancing OL development13,14, whether epigenetic dysregulation of schizophrenia risk factors affects OL function is not understood. These are important questions in understanding the OL-related and myelin-related pathogenesis of psychiatric diseases, but are unfortunately understudied.

The Fasciculation and Elongation Protein Zeta-1 (FEZ1) is a well-recognized schizophrenia risk factor. Genetic alterations in the FEZ1 gene are found in schizophrenia patients15,16. In addition, reduced FEZ1 expression is observed in schizophrenia postmortem brains17. The FEZ1 protein interacts with the disrupted in schizophrenia 1 (DISC1), which is indicated in multiple neuropsychiatric disorders, including schizophrenia18. In particular, an epistatic interaction between FEZ1 and DISC1 is reported to increase the risk of schizophrenia19. In animal models, genetic deletion of the mouse Fez1 gene results in hyperactivity and enhanced responsiveness to psychostimulants20. Functionally, FEZ1 belongs to a family of adhesion proteins known to govern neuronal axon growth and fasciculation21. Moreover, FEZ1–DISC1 interaction controls proper dendritic arbor growth of newborn neurons in the adult mouse hippocampus19. However, whether FEZ1 is expressed in OL cells and FEZ1 deficiency contributes to OL impairment in schizophrenia has not been investigated.

In this study, we report that FEZ1 is expressed in rodent and human OL lineage cells, which is vigorously upregulated during oligodendroglia progenitor cell (OPC) differentiation and myelinogenesis, essential for advancing OL development. Moreover, we identified a molecular orchestra that controls FEZ1 expression in OL by sophisticated transcriptional and post-transcriptional mechanisms, which contain multiple factors dysregulated in schizophrenia. These observations provide the first evidence indicating the functional importance of FEZ1 in OL. Furthermore, our study decodes the coordination of multiple schizophrenia-affected genes that converge on regulation of FEZ1 in OL, offering a model to explain how malfunction of distinct risk factors can lead to common abnormalities in the pathogenesis of psychiatric disorders.

Materials and methods

Animals

The quakingviable (qkv) mouse colony (Jackson Laboratory) and the transgenic mouse line that expresses the OL-specific Flag-QKI-6 transgene were described previously22. To introduce the transgene into the qkv/qkv background (q/q), the male qkv/wt mice (q/w) that carry the QKI-6 transgene were mated with q/q female mice, and the q/q descendants that carry the QKI-6 transgene (q/qtg) were identified using PCR genotyping. Both male and female mice at the age of 2–3 months were used. All the animals within each genotype were randomly picked for experimental analysis. Animal treatment was according to the National Institutes of Health regulations under the approval of the Emory University Institutional Animal Care and Use Committee.

Cell culture, treatment, and transfection

Immunopanning purification of OPCs was performed as previously described23. Primary cortical neurons were raised using embryonic day 18 Wistar rats24. The OPC cell line CG4 was propagated and induced for differentiation as previously described25. When indicated, primary cultured rat OPCs, neurons, and CG4 cells were treated with 50 ng/ml trichostatin A (TSA, Sigma) for 24 h before extraction of RNA or protein. PCDNA3.1, PC-Flag-SOX10, and PC-Flag-ID4 were transfected using Lipofectamine™ 2000 according to the manufacturer’s protocol (Thermo Fisher Scientific, Rockford, IL). Human induced pluripotent stem cell (iPSCs; passage ≤35) were cultured as previously described26. The detailed procedures for differentiation of human iPSCs into OPCs are described in Supplementary Information.

Knockdown of FEZ1 by siRNA and lentivirus-expressed shRNA

A previously validated FEZ1 short interfering RNA (siRNA; 5′-GCTTGAGAATTTTTCTTCC-3′)27 or a negative control siRNA (ID# AM4611, Ambion) were co-transfected with EGFP-C2 (Clontech, CA) into CG4 cells. In addition, a lentivirus-encoded shRNA that targets the aforementioned FEZ1 mRNA sequence or a negative control shRNA was used to transduce rat primary OPCs. During acquisition, digital images were captured in randomly picked microscopic fields for each transfection experiment. Experimenters were blinded to treatment and analysis for cell morphology studies as described25. Days for various treatments of cultures are indicated in the corresponding legends.

Immunoblot, immunocytochemistry, and RT-PCR

Immunoblot, immunocytochemistry PCR, and quantitative RT-PCR (RT-qPTR) were performed as previously described28,29. Antibodies and primers used are provided in the Supplementary Information.

UV crosslinking immunoprecipitation and chromatin IP (ChIP)

Crosslinking immunoprecipitation (CLIP) was performed as previously described with modifications22. C57BL/6 mouse brainstems were minced and subjected to UV crosslinking. The post-nuclear supernatant was isolated from tissue lysates, precleared, and incubated with anti-Flag M2 beads (Sigma) for 2 h at 4 °C. After extensive washes, the immunoprecipitated complexes were eluted with 0.1 mg/ml Flag peptide. RNA was extracted and followed by RT-PCR.

For ChIP, cells were fixed in 3.4% formaldehyde in 1 × PBS buffer before being lysed and subjected to IP using anti-Histone H3-AcK9 antibody conjugated to protein A beads as described24. The immunoprecipitated genomic DNA was subjected to qPCR using primers specific to the Fez1 promoter region and was normalized to the amount of the input DNA of each sample.

Identification of putative transcription factor-binding sites at the Fez1 promoter

JASPAR (http://jaspar.genereg.net/), a database of known transcription factor (TF)-binding sites from the experiment-based literature30, was used to predict putative TF binding to the rat Fez1 promoter (1000 bp upstream of the transcription start site; Supplementary Table S1). Relative profile score threshold was set as 80%, which is the default parameter in JASPAR database.

Statistical analysis

All statistical analyses were performed with GraphPad Prism 5 software (GraphPad Software Inc.). For two-sample comparisons, independent two-sided t-test with or without Welch’s correction was applied. For three-sample comparisons, one-way ANOVA analysis and turkey post hoc test were used as indicated in the corresponding figure legends. All graphs were presented as means ± SEM. Statistical significances were indicated by *(P < 0.05) or **(P < 0.01).

Results

FEZ1 is expressed in OL lineage cells and deposited to the growing processes

To determine whether FEZ1 is expressed in OL lineage cells, we first performed immunofluorescence (IF) staining using an antibody that recognizes the highly conserved FEZ1 protein (green) in rodents and human. OL cells at various differentiation stages were co-stained using well-established markers (red). FEZ1 was mainly detected in the cytoplasm of CC1-labeled mature OL cells in the mouse corpus callosum (Fig. 1a) and mature rat OL cells raised in primary culture that express myelin basic protein (MBP, Fig. 1b). Further analysis detected FEZ1 in rat OPCs (Figs. 1c, e), and OL differentiated from human iPSCs indicated by Olig2 staining (Fig. 1d). Notably, FEZ1 was deposited in the growing processes and enlarged tips (Figs. 1b, c, e). In addition, FEZ1 IF signals were also strongly detected in the growing processes of CG4 cells, a widely used OPC cell line that can be induced for morphogenetic differentiation to mimic primary OPCs (Fig. 1f). Colocalization of FEZ1 with F-actin in the tips of OPCs (Fig. 1e) and CG4 cells (Figs. 1f, g) was detected. Moreover, consistent with the microtubule-related function of FEZ1 in neurons31, FEZ1 colocalized with β-tubulin-labeled microtubule tracts in the distal processes of differentiating CG4 cells (Fig. 1h). These results demonstrate that FEZ1 is expressed in OL lineage cells and is associated with the cytoskeleton in OL distal processes.

Fig. 1
figure1

Expression and subcellular localization of FEZ1 in OL lineage cells. ad Representative immunofluorescent images of FEZ1 (green) with OL markers (red) for different developmental stages. a Mature oligodendrocytes in the mouse corpus callosum marked by CC1; b primary cultured mature rat oligodendrocyte marked by MBP; c rat OPCs marked by NG2; and d human iPSC-derived OL marked by Olig2. e, f Enrichment of FEZ1 (green) in the enlarged distal tips of primary rat OPCs (e) and the OPC cell line CG4 (f). The leading edge is marked by phalloidin that stains F-actin (red). g A representative image for colocalization of FEZ1 (green) and phalloidin (red) in distal tips of CG4 processes. h Double-staining of FEZ1 (green) and β-tubulin (red) in CG4 processes. Scale bar in (ae) 20 μm. Scale bar in F = 40 μm. Scale bar in (g, h) 10 μm

FEZ1 is upregulated during OL and myelin development, essential for advancing OL processes' development

To determine whether and how FEZ1 is regulated during OL development, we analyzed FEZ1 protein abundance by immunoblotting in primary cultured OPCs that underwent differentiation. As shown in Figs. 2a, b, FEZ1 protein levels were significantly increased on differentiation day 4 (Dif4) in comparison to undifferentiated proliferating OPCs (Pro). RT-qPCR further indicated increased FEZ1 mRNA on Dif4 (Fig. 2c). In addition, upregulation of FEZ1 protein was detected in optic nerves during the most vigorous myelinogenesis between postnatal days 14 and 30 (Figs. 2d, e), accompanied with similar folds of increase of FEZ1 mRNA (Fig. 2f). Although FEZ1 protein and mRNA were also upregulated during neuronal differentiation (Supplementary Fig. S1), FEZ1 mRNA in the optic nerve is primarily derived from the highly enriched oligodendroglial cells, whereas neuronal mRNAs are largely restricted in the soma and dendrites, but are negligible in mature axons. Thus, increased FEZ1 mRNA expression is likely the driving force for upregulation of FEZ1 protein in OL during differentiation and myelinogenesis.

Fig. 2
figure2

Upregulation of FEZ1 during OL differentiation in culture and myelin development in the optic nerve. a Representative immunoblot of FEZ1 protein in purified rat OPCs that underwent proliferation (Pro) or 4 days of differentiation in culture (Dif4). b Quantification of FEZ1 protein levels on immunoblot of primary OPC cultures (n = 4, Welch’s correction was applied). c Quantification of FEZ1 mRNA in primary OPC cultures by RT-qPCR (n = 4). d Representative immunoblot of FEZ1 protein in optic nerves on postnatal day 14 (P14) and day 30 (P30). e Quantification of FEZ1 protein levels on immunoblot of optic nerves (n = 4). f Quantification of FEZ1 mRNA in optic nerves by RT-qPCR (n = 5). β-actin was used as a loading control

To directly access the function of FEZ1 in OL development, we generated a lentivirus that encodes a short-hairpin RNA (shRNA), specifically targeting a previously validated site in the FEZ1 mRNA27. Acute knockdown of FEZ1 (Fig. 3a) in purified rat OPCs significantly attenuated the growth and branching of OL processes (Figs. 3b, c). In addition, we also carried out siRNA-mediated knockdown of FEZ1 in CG4 cells (Fig. 3d), which can be induced for differentiation in a synchronized manner32. Similar to primary OPCs, knockdown of FEZ1 in CG4 cells significantly attenuated processes' complexity (Figs. 3e, f). However, the proliferation of OPCs was not affected by FEZ1 knockdown (Supplementary Fig. S2). Together, these results suggest that FEZ1 plays essential roles in promoting OL processes' arbor development during early differentiation.

Fig. 3
figure3

Knockdown of FEZ1 reduces the growth of OL processes. a Representative immunoblot of FEZ1 protein in primary OPCs treated by a lentivirus expressing control shRNA (Ctrsh) or FEZ1 shRNA (FEZ1sh). Densitometer readings of FEZ1 signal normalized to the loading reference β-actin are displayed underneath. b Representative images of primary OPCs treated with control shRNA or FEZ1 shRNA that underwent 72 h of differentiation. EGFP is expressed by the lentivirus for identification of infected cells. c Quantitative analysis of morphology of rat primary OPCs. Percentages of cells that harbor the highest order of process branches as primary (1°), secondary (2°), tertiary (3°), and quaternary (4°) were calculated. Data are expressed as mean ± SEM of three independent experiments (n = 353 cells in control shRNA, n = 390 cells in FEZ1 shRNA). d Representative immunoblot of FEZ1 protein in CG4 cells treated with control siRNA (Ctrsi) or FEZ1 siRNA (FEZ1si). Densitometer readings of FEZ1 signal normalized to the loading reference β-actin are displayed underneath. e Representative images of CG4 cells transfected with control siRNA or FEZ1 siRNA that underwent 48 h of differentiation. EGFP marks co-transfected cells. f Quantitative analysis of CG4 cell morphology as described in (c; n = 123 for each group). Scale bar = 20 μm

FEZ1 expression in OL is regulated by a functional interplay between histone deacetylation and TFs affected in psychiatric diseases

Considering the critical roles of histone deacetylase (HDAC)-dependent transcriptional regulation in advancing OL differentiation, we next questioned whether FEZ1 is regulated by HDAC activity in OL. Differentiating rat OL cells were treated with the HDAC inhibitor TSA. Surprisingly, in contrast to the well-documented activity of TSA for transcriptional induction through histone acetylation-mediated chromatin modification33, a significant downregulation of FEZ1 mRNA was observed in TSA-treated primary OL cells (Fig. 4a) and CG4 cells (Fig. 4b). Immunoblot confirmed an overall increase of acetylated histone 3 at K9 (acH3K9) by TSA (Supplementary Fig. S3A). In contrast, TSA treatment did not change FEZ1 mRNA levels in primary cultured cortical neurons (Supplementary Fig. S4), suggesting that HDAC-dependent regulation of FEZ1 is OL-specific. Conversely, TSA markedly induced the mRNAs of the cyclin-dependent kinase 5 activator P39 in neurons (Supplementary Fig. S3C). In addition, chromatin immunoprecipitation (ChIP)-qPCR of acH3K9, a surrogate marker for increased accessibility of genomic DNA to TFs34, demonstrated effective immunoprecipitation of overall acH3K9 (Fig. 4c) but increased acH3K9 at the Fez1 promoter region in OPCs and CG4 cells (Fig. 4d). These results indicate that TSA-induced increase of FEZ1 promoter accessibility leads to OL-specific FEZ1 downregulation; raising an intriguing possibility that FEZ1 transcription may be predominantly regulated by transcription repressors in OL cells.

Fig. 4
figure4

The cooperation between HDAC-dependent histone acetylation and transcription factors controls FEZ1 expression in OL. a, b FEZ1 mRNA levels in primary cultured OPCs that underwent 5 days of differentiation (DIV5; a; n = 4) and CG4 cells b (n = 5) were treated with TSA or DMSO for 24 h. c Western blot shows comparable efficiency of acH3K9 immunoprecipitation in DMSO or TSA-treated CG4 cells. d Representative illustration of increased acH3K9 at the FEZ1 promoter upon TSA treatment based on ChIP–PCR (upper panel) in rat OL and CG4 cells. ChIP–qPCR quantification of acH3K9 at the FEZ1 promoter in CG4 cells was normalized to the total input of genomic DNA and was graphically displayed (lower panel, n = 7). e, f RT-qPCR quantification of transcription repressor (FOXG1, ID2, ID4) mRNAs e and transcription activator (SOX10, TCF4, SOX6) mRNAs f in DMSO-treated or TSA-treated CG4 cells (n = 5, Welch’s correction was applied). g Representative immunoblot of Flag-ID4 expressed in CG4 cells (upper panel), which leads to downregulation of the FEZ1 mRNA detected by RT-qPCR (lower panel, n = 6 in CTL, n = 8 in Flag-ID4). h Representative immunoblot of Flag-SOX10 in CG4 cells (upper panel), which increases FEZ1 mRNA detected by RT-qPCR (lower panel, n = 5). i Expression of Flag-ID4 in CG4 cells leads to downregulation of the activator TFs (SOX10, TCF4, SOX6) mRNAs detected by RT-qPCR (n = 8 in CTL, n = 6 in Flag-ID4)

We searched for TFs that may bind rat Fez1 promoter, especially focusing on repressor TFs that decline during OPC differentiation and thus may underlie the developmentally programmed FEZ1 upregulation. The JASPAR algorithm identified 349 TFs predicted to bind both the rat and the human Fez1 promoter, respectively (Supplementary Fig. S5A). Approximately 90% of these TFs are predicted to bind a 500 bp region immediately upstream of the Fez1 transcription start site, which is highly conserved in rat and human (Supplementary Fig. S5B). We found that 106 of the predicted Fez1 promoter-binding TFs were expressed in OPC and mature OL cells documented by RNA-seq (Supplementary Fig. S5C)35. A majority of these OPC-expressed Fez1 promoter-binding TFs were downregulated in mature OL. In addition, 30 predicted Fez1 promoter-binding TFs were found in an independent microarray study that documents transcriptome changes at specific stages of OPC differentiation (Supplementary Fig. S5D and Supplementary Table S1)36. When cross-referenced, 20 predicted Fez1 promoter-binding TFs were found in both OL databases, which are regulated during early OL differentiation along with FEZ1 upregulation. Strikingly, a majority of these predicted Fez1 promoter-binding TFs were dysregulated in neuropsychiatric disorders (Supplementary Table S1).

We selected a number of developmentally regulated Fez1 promoter-binding TFs identified in both OL databases and dysregulated in neuropsychiatric diseases, and tested whether they are regulated by TSA thus may underlie FEZ1 downregulation. Interestingly, TSA increased expression of several repressor TFs that are predicted to bind Fez1 promoter, including FOXG1, ID2, and ID4 (Fig. 4e). Conversely, activator TFs predicted to bind Fez1 promoter were downregulated by TSA, including SOX10, TCF4, and SOX6 (Fig. 4f). Notably, previous studies reported an aberrant increase of the repressor TF ID4 in schizophrenia patient brains and reduction of the OL-specific activator TF SOX10 in the brains of schizophrenia, bipolar, and major depression postmortem cohorts (Supplementary Table S1). We thus tested whether ID4 and SOX10 can regulate endogenous FEZ1 expression. Indeed, Flag-ID4 reduced FEZ1 mRNA in CG4 cells (Fig. 4g), whereas Flag-SOX10 increased FEZ1 mRNA (Fig. 4h). Moreover, consistent with the idea that repressor TFs play dominant roles, Flag-ID4 significantly downregulated multiple OL-specific activator TFs that are predicted to bind FEZ1 promoter (Fig. 4i). Thus, ID4-mediated downregulation of FEZ1 may involve direct transcriptional inhibition of FEZ1 by binding the FEZ1 promotor, as well as a cross-suppression of FEZ1 by reducing activator TFs that function to enhance FEZ1 transcription. Together, these data suggest that FEZ1 transcription in OL is governed by functional cooperation between HDAC-dependent chromatin modulation and OL-specific TFs that are susceptible to dysregulation in neuropsychiatric diseases.

The Quaking I (QKI) RNA-binding protein is essential for FEZ1 expression in OL

Besides transcription, post-transcriptional mechanisms also play key roles in controlling mRNA abundance and promoting OL development. We found that human, mouse, and rat FEZ1 3’ untranslated regions harbor two consensus Quaking response elements (Fig. 5a). These are well-known sequence motifs controlling mRNA stability through interaction with the RNA-binding protein QKI, a glia-expressed schizophrenia risk factor37,38, essential for OL and myelin development25. Indeed, FEZ1 mRNA was co-immunoprecipitated with the Flag-tagged QKI-6 cytoplasmic isoform (Tg, Fig. 5b), which is specifically expressed in OL22. Consistent with the essential role of QKI in stabilization of its mRNA ligands, FEZ1 mRNA was markedly reduced in optic nerves of the homozygous quakingviable (qkv) hypomyelination mutant mice (q/q, Fig. 5c) that harbor OL-specific QKI deficiency39. The reduction of FEZ1 in q/q optic nerves was completely rescued by Flag-QKI-6 (q/qtg, Fig. 5c)22. Unlike FEZ1, DISC1 mRNA was not regulated by QKI (Fig. 5d). Moreover, in contrast to optic nerves, FEZ1 expression was not affected by QKI deficiency in the hippocampi of the q/q mutant mice (Fig. 5e), which harbor small numbers of OL cells but enriched in neurons. Hence, QKI deficiency only affected FEZ1 expression specifically in OL but not in neurons. Furthermore, IF staining demonstrated diminished FEZ1 protein in CC1 + mature OLs in the corpus callosum of the q/q mutant mice, which can be rescued by transgenic expression of Flag-QKI-6 (Fig. 5f). These results suggest that QKI binds and stabilizes FEZ1 mRNA in the OL cytoplasm, hence connecting the function of FEZ1 in OL with this glia-specific schizophrenia risk factor at the level of post-transcriptional regulation.

Fig. 5
figure5

Post-transcriptional regulation of FEZ1 mRNA by cytoplasmic QKI. a Schematic illustration (left) of two Quaking response elements (QRE) located at 3’ UTR of FEZ1 mRNA. The QRE motif sequences of human, mouse, and rat QRE motifs are aligned on the right. The consensus QRE sequences are marked in blue. b UV-crosslink immunoprecipitation (CLIP) followed by RT-PCR revealed that interaction of FEZ1 mRNA with Flag-QKI-6 expressed specifically in brain OL of transgenic mice (Tg). Non-transgene (N-Tg) mice were used as a negative control. RT-PCR of the GAPDH mRNA that does not interact with QKI-6 was used as a negative control for specificity. c QKI deficiency in the homozygous quakingviable (qkv) mutant mice (q/q) affects FEZ1 mRNA abundance in OL, which can be rescued by the Flag-QKI-6 transgene. The FEZ1 mRNA levels in optic nerves of qkv/WT (q/w), qkv/qkv (q/q), and q/qtg mice (n = 6) were quantified by RT-qPCR followed by one-way ANOVA analysis and Tukey post hoc test. d RT-qPCR of DISC1 mRNA in the optic nerves of q/w, q/q, and q/qtg mice (n = 4). e RT-qPCR of FEZ1 mRNA in the hippocampus of q/w, q/q, and q/qtg mice (n = 4). f Immunocytochemistry of FEZ1 (green) in mature oligodendrocytes marked by CC1 (red) in the corpus callosum of q/w, q/q, and q/qtg mice. Arrows indicated diminished FEZ1 protein in CC1 + cells from the q/q mice. Scale bar = 25 μm

Discussion

Our studies revealed that FEZ1 is expressed in the OL lineage throughout development and plays essential roles to promote formation of OL process arbors. Moreover, we identified a number of sophisticated molecular pathways that cooperate to govern FEZ1 expression in OL at transcriptional and post-transcriptional steps, linking FEZ1 with multiple regulators crucial for governing OL development but susceptible to genetic mutations and/or epigenetic dysregulation in psychiatric disorders. A working model for this multifactorial susceptibility mechanism of psychiatric illnesses is illustrated in Supplementary Figure S6.

Although the function of FEZ1 in neuronal development is well documented19,21, previous studies did not address whether FEZ1 is expressed in OL and how FEZ1 deficiency may be connected with OL impairment in neuropsychiatric diseases. Here we showed for the first time that FEZ1 is expressed in rodent and human OL lineage cells. In addition, acute knockdown of FEZ1 in OPCs significantly attenuated development of OL processes, suggesting an essential role of FEZ1 in early OL differentiation. Given the highly conserved FEZ1 amino-acid sequence (data not shown), FEZ1 most likely also functions to promote human OL development. In this regard, genetic alterations that result in FEZ1 deficiency and/or malfunction will affect not only neurons but also OL lineage cells, which contribute to the OL etiology in psychiatric diseases.

The roles of FEZ1 in promoting the growth of OL processes recapitulate its well-characterized function in axonal and dendritic arbor formation of neurons19,21,40, suggesting a functional analogy of FEZ1 in both the neuronal and the OL lineages. The marked upregulation of FEZ1 during differentiation of both OL and neurons suggests an increased functional requirement of FEZ1 to support the most vigorous growth of neural cell processes. In the developing hippocampal neurons, FEZ1 is found in growth cones and is associated with F-actins41. More recent studies revealed that FEZ1 also acts as a kinesin-1 adaptor and plays important roles in axonal transport and presynaptic specification31,42. We found that FEZ1 colocalized with F-actin and microtubule fibers in the growing processes and distal tips of OL cells, suggesting that FEZ1–cytoskeleton interaction likely underlies OL process development, similar to its function in neuronal network formation.

Establishing the complex OL process arbors is an important step before myelin sheath formation43. Myelinogenesis in vivo requires coordination between oligodendrocytes and axons, which involves both cell autonomous mechanisms and OL–axon interactions44. We observed a marked increase of FEZ1 during differentiation of purified neurons and OL in culture. Moreover, FEZ1 is upregulated in the optic nerve during rigorous myelination (Fig. 2), suggesting that FEZ1 may also promote myelin formation. Thus, FEZ1 upregulation may serve as a mechanism for coordination between myelinating oligodendrocytes and neurons during myelinogenesis. Whether FEZ1 indeed promotes myelin development in vivo still remains unexplored. Conventional knockout of Fez1 in mice causes schizophrenia-related behavioral abnormalities without gross defects in the adult brain20. However, Fez1 function in OL and myelin development in vivo has not been carefully examined, which warrants future investigation in a conditional Fez1 knockout mouse model. It is important to point out that, besides the classical function of myelination, the non-myelinating roles of OL also modulate neuronal function, such as trophic and/or metabolic support and neurotransmitter release45,46,47,48. Whether FEZ1 may also support non-myelination functions of OL is the next challenge for future studies.

FEZ1 expression in OL is regulated by a sophisticated molecular orchestra. First, HDAC inhibition increases histone acetylation at the FEZ1 promoter but reduces FEZ1 mRNA specifically in OL cells. The TSA-induced FEZ1 downregulation recapitulates OL genes that play key roles in promoting OL differentiation, such as Sox10 and Tcf4 (Fig. 4). In contrast, HDAC inhibition selectively enhances expression of repressor genes represented by Id4, which were downregulated during early OL differentiation. Hence, in contrast to TSA-induced neuronal differentiation49, TSA ablates OL differentiation and myelinogenesis50. It is postulated that transcription in OPCs is predominantly controlled by repressor TFs that prevent OL differentiation. HDAC-mediated histone deacetylation causes chromatin condensation in OPCs, which downregulates differentiation suppressor TFs and reduces their accessibility to differentiation-promoting genes, including FEZ1, to permit OL differentiation51. Besides direct suppression of FEZ1, repressor TFs also cross-inhibit OL-specific activator TFs that act to increase FEZ1 transcription (Fig. 4). The conserved Fez1 promoter sequence and TFs in rat and human suggest that the rat OL transcriptional pathways that regulate FEZ1 identified here are also present in human OL. Interestingly, a number of repressor TFs predicted to bind Fez1 promoter are aberrantly increased in brains of mental illness, whereas activators TFs for FEZ1 are reduced (Supplementary Table S1), similar to the effects in OL upon TSA treatment. This raises an intriguing possibility that aberrant histone acetylation, perhaps due to malfunction of HDACs, may selectively affect multiple key players in OL development beyond FEZ1, which underlies OL-specific etiology of mental illnesses.

Besides connecting FEZ1 with TFs that are dysregulated in psychiatric disorders, our studies also identified FEZ1 as a downstream target of QKI-dependent post-transcriptional regulation, which is essential for OL differentiation and myelinogenesis25,52. QKI is a glia-specific risk factor for schizophrenia, not expressed in brain neurons53. In addition to the clusters of single-nucleotide polymorphisms in human QKI that co-segregate with schizophrenia, reduced QKI expression is observed in the postnatal brains of multiple schizophrenia cohorts37,54. There are three QKI isoforms derived from alternative splicing39, which display distinct nuclear–cytoplasmic distribution and regulate target mRNAs at various post-transcriptional steps22. The human and mouse QKI protein isoforms are identical. The q/q mutant mice harbor deficiency of all QKI isoforms and diminished FEZ1 mRNA specifically in OL cells, which can be rescued by the cytoplasmic isoform QKI-6, suggesting that QKI controls FEZ1 mRNA stability in the OL cytoplasm. Together, our results reveal an OL-specific mechanism for regulating FEZ1 expression at transcriptional and post-transcriptional levels; both are susceptible to dysregulation in schizophrenia.

A rapidly growing list of susceptibility genes for schizophrenia has been identified. How malfunction of distinct risk factors leads to the common pathophysiology in schizophrenia is a prevailing question in understanding the pathogenesis of psychiatric disorders. The sophisticated regulatory pathways that secure the abundance of FEZ1 in OL contain numerous risk factors affected in psychiatric diseases. Thus, malfunction of different factor(s) can converge on FEZ1 deficiency in schizophrenia. In this regard, our study on FEZ1 provides an example how multiple risk factors are functionally connected in schizophrenia, which leads to OL impairment.

References

  1. 1.

    Kubicki, M., McCarley, R. W. & Shenton, M. E. Evidence for white matter abnormalities in schizophrenia. Curr. Opin. Psychiatry 18, 121–134 (2005).

  2. 2.

    Martins-de-Souza, D. Proteome and transcriptome analysis suggests oligodendrocyte dysfunction in schizophrenia. J. Psychiatr. Res. 44, 149–156 (2010).

  3. 3.

    Fields, R. D. White matter in learning, cognition and psychiatric disorders. Trends Neurosci. 31, 361–370 (2008).

  4. 4.

    Edgar, N. & Sibille, E. A putative functional role for oligodendrocytes in mood regulation. Transl. Psychiatry 2, e109 (2012).

  5. 5.

    DeQuardo, J. R. et al. Landmark-based morphometric analysis of first-episode schizophrenia. Biol. Psychiatry 45, 1321–1328 (1999).

  6. 6.

    Bachmann, S. et al. Corpus callosum in first-episode patients with schizophrenia--a magnetic resonance imaging study. Psychol. Med. 33, 1019–1027 (2003).

  7. 7.

    Walterfang, M. et al. Corpus callosum size and shape in first-episode affective and schizophrenia-spectrum psychosis. Psychiatr. Res. 173, 77–82 (2009).

  8. 8.

    Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511, 421–427 (2014).

  9. 9.

    Gejman, P. V., Sanders, A. R. & Duan, J. The role of genetics in the etiology of schizophrenia. Psychiatr. Clin. North Am. 33, 35–66 (2010).

  10. 10.

    Kirov, G. et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol. Psychiatry 17, 142–153 (2012).

  11. 11.

    Fromer, M. et al. De novo mutations in schizophrenia implicate synaptic networks. Nature 506, 179–184 (2014).

  12. 12.

    Millan, M. J. An epigenetic framework for neurodevelopmental disorders: from pathogenesis to potential therapy. Neuropharmacology 68, 2–82 (2013).

  13. 13.

    Shen, S. M., Li, J. D. & Casaccia-Bonnefil, P. Histone modifications affect timing of oligodendrocyte progenitor differentiation in the developing rat brain. J. Cell. Biol. 169, 577–589 (2005).

  14. 14.

    Marin-Husstege, M., Muggironi, M., Liu, A. & Casaccia-Bonnefil, P. Histone deacetylase activity is necessary for oligodendrocyte lineage progression. J. Neurosci. 22, 10333–10345 (2002).

  15. 15.

    Lewis, C. M. et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am. J. Hum. Genet. 73, 34–48 (2003).

  16. 16.

    Yamada, K. et al. Association analysis of FEZ1 variants with schizophrenia in Japanese cohorts. Biol. Psychiatry 56, 683–690 (2004).

  17. 17.

    Lipska, B. K. et al. Expression of DISC1 binding partners is reduced in schizophrenia and associated with DISC1 SNPs. Hum. Mol. Genet. 15, 1245–1258 (2006).

  18. 18.

    Blackwood, D. H. et al. Schizophrenia and affective disorders--cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. Am. J. Hum. Genet. 69, 428–433 (2001).

  19. 19.

    Kang, E. C. et al. Interaction between FEZ1 and DISC1 in regulation of neuronal development and risk for schizophrenia. Neuron 72, 559–571 (2011).

  20. 20.

    Sakae, N. et al. Mice lacking the schizophrenia-associated protein FEZ1 manifest hyperactivity and enhanced responsiveness to psychostimulants. Hum. Mol. Genet. 17, 3191–3203 (2008).

  21. 21.

    Bloom, L. & Horvitz, H. R. The Caenorhabditis elegans gene unc-76 and its human homologs define a new gene family involved in axonal outgrowth and fasciculation. Proc. Natl. Acad. Sci. USA 94, 3414–3419 (1997).

  22. 22.

    Zhao, L., Tian, D., Xia, M., Macklin, W. B. & Feng, Y. Rescuing qkV dysmyelination by a single isoform of the selective RNA-binding protein QKI. J. Neurosci. 26, 11278–11286 (2006).

  23. 23.

    Lee, S., Chong, S. Y. C., Tuck, S. J., Corey, J. M. & Chan, J. R. A rapid and reproducible assay for modeling myelination by oligodendrocytes using engineered nanofibers. Nat. Protoc. 8, 771–782 (2013).

  24. 24.

    Li, W. Q. et al. p39 is responsible for increasing Cdk5 activity during postnatal neuron differentiation and governs neuronal network formation and epileptic responses. J. Neurosci. 36, 11283–11294 (2016).

  25. 25.

    Chen, Y. T., Tian, D. H., Ku, L., Osterhout, D. J. & Feng, Y. The selective RNA-binding protein quaking I (QKI) is necessary and sufficient for promoting oligodendroglia differentiation. J. Biol. Chem. 282, 23553–23560 (2007).

  26. 26.

    Wen, Z. et al. Synaptic dysregulation in a human iPS cell model of mental disorders. Nature 515, 414–418 (2014).

  27. 27.

    Malikov, V. et al. HIV-1 capsids bind and exploit the kinesin-1 adaptor FEZ1 for inward movement to the nucleus. Nat. Commun. 6, 6660 (2015).

  28. 28.

    Zhao, L. X., Mandler, M. D., Yi, H. & Feng, Y. Quaking I controls a unique cytoplasmic pathway that regulates alternative splicing of myelin-associated glycoprotein. Proc. Natl. Acad. Sci. USA 107, 19061–19066 (2010).

  29. 29.

    Mei, F. et al. Identification of the kappa-opioid receptor as a therapeutic target for oligodendrocyte remyelination. J. Neurosci. 36, 7925–7935 (2016).

  30. 30.

    Mathelier, A. et al. JASPAR 2016: a major expansion and update of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 44(D1), D110–D115 (2016).

  31. 31.

    Blasius, T. L., Cai, D., Jih, G. T., Toret, C. P. & Verhey, K. J. Two binding partners cooperate to activate the molecular motor Kinesin-1. J. Cell. Biol. 176, 11–17 (2007).

  32. 32.

    Louis, J. C., Magal, E., Muir, D., Manthorpe, M. & Varon, S. CG-4, a new bipotential glial cell line from rat brain, is capable of differentiating in vitro into either mature oligodendrocytes or type-2 astrocytes. J. Neurosci. Res. 31, 193–204 (1992).

  33. 33.

    Yoshida, M., Kijima, M., Akita, M. & Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265, 17174–17179 (1990).

  34. 34.

    Grunstein, M. Histone acetylation in chromatin structure and transcription. Nature 389, 349–352 (1997).

  35. 35.

    Cahoy, J. D. et al. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J. Neurosci. 28, 264–278 (2008).

  36. 36.

    Swiss, V. A. et al. Identification of a gene regulatory network necessary for the initiation of oligodendrocyte differentiation. PLoS. ONE 6, e18088 (2011).

  37. 37.

    Aberg, K. et al. Human QKI, a new candidate gene for schizophrenia involved in myelination. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141B, 84–90 (2006).

  38. 38.

    Aberg, K., Saetre, P., Jareborg, N. & Jazin, E. Human QKI, a potential regulator of mRNA expression of human oligodendrocyte-related genes involved in schizophrenia. Proc. Natl. Acad. Sci. USA 103, 7482–7487 (2006).

  39. 39.

    Hardy, R. J. et al. Neural cell type-specific expression of QKI proteins is altered in quakingviable mutant mice. J. Neurosci. 16, 7941–7949 (1996).

  40. 40.

    McIntire, S. L., Garriga, G., White, J., Jacobson, D. & Horvitz, H. R. Genes necessary for directed axonal elongation or fasciculation in C. elegans. Neuron 8, 307–322 (1992).

  41. 41.

    Miyoshi, K. et al. Disrupted-In-Schizophrenia 1, a candidate gene for schizophrenia, participates in neurite outgrowth. Mol. Psychiatry 8, 685–694 (2003).

  42. 42.

    Butkevich, E. et al. Phosphorylation of FEZ1 by microtubule affinity regulating kinases regulates its function in presynaptic protein trafficking. Sci. Rep. 6, 26965 (2016).

  43. 43.

    Hardy, R. J. & Friedrich, V. L. Jr. Progressive remodeling of the oligodendrocyte process arbor during myelinogenesis. Dev. Neurosci. 18, 243–254 (1996).

  44. 44.

    Piaton, G., Gould, R. M. & Lubetzki, C. Axon-oligodendrocyte interactions during developmental myelination, demyelination and repair. J. Neurochem. 114, 1243–1260 (2010).

  45. 45.

    Chen, X. et al. Impairment of oligodendroglia maturation leads to aberrantly increased cortical glutamate and anxiety-like behaviors in juvenile mice. Front. Cell. Neurosci. 9, 467 (2015).

  46. 46.

    Roy, K. et al. Loss of erbB signaling in oligodendrocytes alters myelin and dopaminergic function, a potential mechanism for neuropsychiatric disorders. Proc. Natl. Acad. Sci. USA 104, 8131–8136 (2007).

  47. 47.

    Funfschilling, U. et al. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature 485, 517–521 (2012).

  48. 48.

    Lee, Y. et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 487, 443–448 (2012).

  49. 49.

    Balasubramaniyan, V. et al. Effects of histone deacetylation inhibition on neuronal differentiation of embryonic mouse neural stem cells. Neuroscience 143, 939–951 (2006).

  50. 50.

    Conway, G. D., O’Bara, M. A., Vedia, B. H., Pol, S. U. & Sim, F. J. Histone deacetylase activity is required for human oligodendrocyte progenitor differentiation. Glia 60, 1944–1953 (2012).

  51. 51.

    Emery, B. & Lu, Q. R. Transcriptional and epigenetic regulation of oligodendrocyte development and myelination in the central nervous system. Cold Spring Harb. Perspect. Biol. 7, a020461 (2015).

  52. 52.

    Sidman, R. L., Dickie, M. M. & Appel, S. H. Mutant mice (Quaking and Jimpy) with deficient myelination in the central nervous system. Science 144, 309–311 (1964).

  53. 53.

    Kondo, T. et al. Genomic organization and expression analysis of the mouse qkI locus. Mamm. Genome 10, 662–669 (1999).

  54. 54.

    Haroutunian, V., Katsel, P., Dracheva, S. & Davis, K. L. The human homolog of the QKI gene affected in the severe dysmyelination “quaking” mouse phenotype: downregulated in multiple brain regions in schizophrenia. Am. J. Psychiatry 163, 1834–1837 (2006).

Download references

Acknowledgments

This work was supported by NIH R01NS093016, NS070526 and NS056097 to Y.F.; NNSFC grant (31671117) and CSTCKJCXLJRC07 to L.X.; China Scholarship Council support (201403170254) to C.X.; NNSFC grant (31471955) to Z.X.; and Emory start-up fund to Z.W.

Author information

Correspondence to Lan Xiao or Yue Feng.

Ethics declarations

Competing interests

The authors declare that they have no competing financial interests.

Additional information

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Spplemental material for 2017TP000313, Chen et al.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading